Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus, single-agent lenvatinib, and single-agent everolimus in patients with renal cell carcinoma (RCC).

The three-arm study looked at patients who previously received sunitinib or pazopanib, Larkin explains. In patients who received everolimus, PFS was approximately 5 months, while PFS was 7 months in patients who received lenvatinib. Patients who received the combination had a median PFS of 14 months.

Toxicities associated with the combination, which included high blood pressure and diarrhea, were manageable and expected.